文献速递胃肠动力与功能性疾病

短肠综合征合并肠衰竭患者对替度鲁肽应答的相关因素

Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
PubMed 文献 · Gastroenterology · 2017-11-22

该研究对一项III期安慰剂对照试验的85例短肠综合征合并肠衰竭患者进行事后分析,评估替度鲁肽对肠外支持量减少的影响。结果显示,替度鲁肽的疗效与基线肠外支持量、肠道解剖分型及疾病特征相关,其中空肠造口/回肠造口组绝对肠外支持量减少最显著。

要点

  • 基线肠外支持量越大,替度鲁肽治疗后的肠外支持量减少越多(r²=0.61,P<.0001)。
  • 空肠造口/回肠造口组替度鲁肽治疗者肠外支持量减少919±644 mL/d,显著大于安慰剂组(340±436 mL/d,P=.0112)及结肠延续≥50%无造口组(355±306 mL/d,P=.0066)。
  • 炎症性肠病相关短肠综合征患者中结肠延续者比例较低(10.5%),而血管疾病及其他疾病患者中较高(84.4%和67.6%)。

核心结论

  • 在短肠综合征合并肠衰竭患者中,替度鲁肽治疗后的肠外支持量减少与基线肠外支持量、肠道解剖及短肠综合征特征相关,这些发现可能有助于初始肠外支持量调整和管理。

研究设计与样本

  • 对一项III期安慰剂对照研究的事后分析,纳入85例短肠综合征合并肠衰竭患者,于2008年11月25日至2011年1月4日在10个国家27个中心接受替度鲁肽或安慰剂治疗。
  • 按基线肠外支持量、肠道解剖(1组:空肠造口/回肠造口;2组:≥50%结肠延续无造口;3组:其他结肠解剖)及疾病特征(炎症性肠病、肠系膜血管疾病或其他)评估肠外支持量变化。
  • 采用简单线性回归模型进行相关性分析,报告未校正r²值;两组比较采用双侧t检验。

主要发现

  • 肠外支持量减少与替度鲁肽治疗及基线肠外支持量相关(y = -0.3870x + 90.0279,r² = 0.61;P < .0001)。
  • 1组患者替度鲁肽治疗后绝对肠外支持量减少919 ± 644 mL/d,显著大于安慰剂组(减少340 ± 436 mL/d;P = .0112),也显著大于2组替度鲁肽治疗者(减少355 ± 306 mL/d;P = .0066)。
  • 替度鲁肽对3组患者的效果居中。
  • 炎症性肠病相关短肠综合征患者中结肠延续者占10.5%(n = 2/19),血管疾病及其他疾病患者中分别占84.4%(n = 27/32)和67.6%(n = 23/34)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Clinical studies showed teduglutide to increase urine production and reduce need for parenteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight absorption and reducing diarrhea. However, the effects of teduglutide on parenteral support vary among patients. We performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response. METHODS: We collected data from 85 patients with SBS with intestinal failure, according to the European Society for Clinical Nutrition and Metabolism classification system, who received teduglutide or placebo between November 25, 2008, and January 4, 2011, at 27 sites in 10 countries. Changes in parenteral support volume were evaluated according to baseline parenteral support volume, bowel anatomy (group 1, jejunostomy/ileostomy; group 2, ≥50% colon-in-continuity without stoma; and group 3, other colon anatomies), and disease features (with inflammatory bowel disease, mesenteric vascular diseases, or other conditions). Correlation analyses were conducted using simple linear regression models, with unadjusted r2 values reported. Two-sided t tests were used for comparisons between treatment groups. RESULTS: We correlated parenteral support volume reduction with teduglutide treatment and baseline parenteral support volume (y = -0.3870x + 90.0279, r2 = 0.61; P < .0001). The effects of teduglutide on absolute parenteral support volume were significantly greater in group 1 patients (reduction of 919 ± 644 mL/d), not only compared with patients given placebo (reduction of 340 ± 436 mL/d; P = .0112) but also compared with teduglutide-treated patients in group 2 (reduction of 355 ± 306 mL/d; P = .0066). Teduglutide had an intermediate effect on patients in group 3. A minority of patients with SBS and inflammatory bowel diseases had colon-in-continuity (10.5% [n = 2/19]), whereas most patients with SBS and vascular or other diseases had colon-in-continuity (84.4% [n = 27/32] and 67.6% [n = 23/34], respectively). CONCLUSIONS: In a post hoc analysis of data from a phase III study of the effects of teduglutide on patients with SBS, we associated reduced parenteral support volume with baseline parenteral support volume, bowel anatomy, and SBS features. These findings may inform initial parenteral support volume adjustments and management of these severely disabled patients. ClinicalTrials.gov no: NCT00798967; ClinicalTrialsRegister.eu no: 2008-006193-15.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Jeppesen PB, Gabe SM, Seidner DL, et al. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. Gastroenterology. 2017. PMID: 29174926. doi:10.1053/j.gastro.2017.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。